[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630136":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":25,"responsibleParty":73,"collaborators":76,"id":81,"slug":82,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":10,"eligibilityCriteria":87,"healthyVolunteers":83,"sex":88,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":10,"studyType":94,"phases":10,"briefSummary":95,"conditions":96,"keywords":102,"overallStatus":107,"whyStopped":10,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"The Children's Hospital of Zhejiang University School of Medicine","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"HEM-SURVIVE Structured Follow-up Mode",null,"Implementation of a structured follow-up system based on exposure-oriented risk stratification (four levels: Minimal, Standard, High, and Ultra-high risk). It includes standardized examination packages (A, A+, B, and C), multidisciplinary (MDT) survivor clinics, and digital management via the HEM-SURVIVE APP.",{"label":13,"type":10,"description":14,"interventionNames":10},"Conventional Follow-up Mode","Routine follow-up practices currently used in China. Examination projects are determined empirically by the attending physician and family, which lacks a unified path and systematic proactive monitoring. Key examinations for late effects are often triggered only after symptoms appear.",[16,21],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Jingying Zhang, MD","CONTACT","+86 571 86670076","zhangjy423@zju.edu.cn",{"name":22,"role":18,"phone":23,"phoneExt":10,"email":24},"Tian Xia, MD","+86 15267035696","xiatian0604@zju.edu.cn",[26,47,59],{"facility":27,"status":10,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Children's hospital, Zhejiang University School of Medicine","Hangzhou","Zhejiang","310000","China","CN",{"type":34,"coordinates":35},"Point",[36,37],120.16142,30.29365,{"lat":37,"lon":36},[40,43,45],{"name":41,"role":18,"phone":42,"phoneExt":10,"email":20},"Jing ying Zhang, MD","86-15968103802",{"name":22,"role":18,"phone":44,"phoneExt":10,"email":24},"86-15267035696",{"name":41,"role":46,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"facility":48,"status":10,"city":28,"state":29,"zip":49,"country":31,"countryCode":32,"cosmosGeoPoint":50,"geoPoint":52,"contacts":53},"Hangzhou Children's Hospital","310014",{"type":34,"coordinates":51},[36,37],{"lat":37,"lon":36},[54,56,57],{"name":55,"role":18,"phone":42,"phoneExt":10,"email":20},"Jing Huang, MD",{"name":22,"role":18,"phone":44,"phoneExt":10,"email":24},{"name":55,"role":58,"phone":10,"phoneExt":10,"email":10},"SUB_INVESTIGATOR",{"facility":60,"status":10,"city":61,"state":29,"zip":62,"country":31,"countryCode":32,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"Affiliated Women and Children's Hospital of Ningbo University","Ningbo","315000",{"type":34,"coordinates":64},[65,66],121.54945,29.87819,{"lat":66,"lon":65},[69,71,72],{"name":70,"role":18,"phone":42,"phoneExt":10,"email":20},"Jian hua Feng, MD",{"name":22,"role":18,"phone":44,"phoneExt":10,"email":24},{"name":70,"role":58,"phone":10,"phoneExt":10,"email":10},{"type":46,"investigatorFullName":74,"investigatorTitle":75,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"zhangjingying","Principal Investigator",[77,79],{"name":78,"class":6},"Ningbo Women & Children's Hospital",{"name":48,"class":80},"UNKNOWN","100630136","hem-survive-structuralized-follow-up-for-childhood-hematological-malignancy-survivors-100630136",false,"NCT07483749","HEM-SURVIVE: Structuralized Follow-up for Childhood Hematological Malignancy Survivors","A Multicenter Prospective Study on Structuralized Follow-up Model Construction and Late Effect Burden of Childhood Hematological Malignancy Survivors (HEM-SURVIVE)","Inclusion Criteria:\n\n* Diagnosed with childhood hematological malignancies (ALL, AML, Lymphoma, etc.), Completed primary treatment for ≥12 months.\n* Age 1-21 years.\n* Capable of completing follow-up and data collection.\n* Informed consent signed.\n\nExclusion Criteria:\n\n* Severe organ failure preventing follow-up.\n* Major genetic or systemic diseases affecting growth\u002Forgan function.\n* Expected poor compliance or refusal to participate.","ALL","1 Year","21 Years",{"count":92,"type":93},400,"ESTIMATED","OBSERVATIONAL","This study aims to construct a structuralized follow-up model for survivors of childhood hematological malignancies in China. Using a multicenter prospective cohort design, it will identify the burden and risk factors of late effects. The study hypothesizes that a standardized follow-up path managed by an electronic platform will improve follow-up compliance and reduce the missed diagnosis rate of late effects.",[97,98,99,100,101],"Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia","Lymphoma","Leukemia","Pediatric",[103,104,105,106],"Survivorship","Late Effects","Follow-up Model,","Risk Stratification","NOT_YET_RECRUITING","2026-03-17",{"date":110,"type":111},"2026-03-19","ACTUAL",{"date":113,"type":93},"2026-03-25",{"date":115,"type":93},"2028-12",{"name":5,"class":6},3]